EL 530

Drug Profile

EL 530

Alternative Names: NaPa; Phenylacetic-acid

Latest Information Update: 20 Dec 2013

Price : $50

At a glance

  • Originator Uniformed Services University of the Health Sciences
  • Class Esters; Phenylacetates; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Hyperammonaemia
  • Discontinued Prostate cancer

Most Recent Events

  • 18 Dec 2013 Elan Corporation has been acquired and merged into Perrigo
  • 25 Aug 1998 Targon no longer holds development rights to EL 530
  • 23 Feb 1998 Launched for Hyperammonaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top